135 related articles for article (PubMed ID: 33363911)
1. Donor cell-derived chronic myelomonocytic leukemia presenting after allogeneic hematopoietic cell transplantation for T-cell acute lymphoblastic leukemia.
Miller KC; Abdel Rahman ZH; Robetorye RS; Foran JM
Clin Case Rep; 2020 Dec; 8(12):3225-3228. PubMed ID: 33363911
[TBL] [Abstract][Full Text] [Related]
2. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
3. Isolated CNS relapse in FLT 3 mutation positive CMML post allogeneic stem cell transplant: Report of a rare case.
Mutreja D; Verma S; Venkatesan S; Sharma S; Das S
Indian J Pathol Microbiol; 2021; 64(1):189-191. PubMed ID: 33433440
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Transplant Cell Ther; 2021 Dec; 27(12):991.e1-991.e9. PubMed ID: 34500124
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan.
Itonaga H; Aoki K; Aoki J; Ishikawa T; Ishiyama K; Uchida N; Sakura T; Ohashi K; Kurokawa M; Ozawa Y; Matsuoka KI; Nakamura Y; Kimura F; Iwato K; Nawa Y; Hirokawa M; Kato K; Ichinohe T; Atsuta Y; Miyazaki Y
Biol Blood Marrow Transplant; 2018 Apr; 24(4):840-848. PubMed ID: 29196081
[TBL] [Abstract][Full Text] [Related]
6. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.
Pan X; Gao M; Sun Y; Zhou Y; Wang K; Wang Y; Xu L; Zhang X; Huang X; Zhao XS
Int J Lab Hematol; 2022 Jun; 44(3):510-517. PubMed ID: 35061336
[TBL] [Abstract][Full Text] [Related]
7. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.
Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Solh M; Bashey A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1816-1822. PubMed ID: 27453362
[TBL] [Abstract][Full Text] [Related]
8. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.
Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Allan D; Bredeson C; Sabloff M; Guru Murthy GS; Badar T; Hashmi S; Aljurf M; Litzow MR; Kebriaei P; Hourigan CS; Saber W
Transplant Cell Ther; 2023 Sep; 29(9):578.e1-578.e9. PubMed ID: 37406882
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.
Arnold SD; Brazauskas R; He N; Li Y; Hall M; Atsuta Y; Dalal J; Hahn T; Khera N; Bonfim C; Hashmi S; Parsons S; Wood WA; Steinberg A; Freytes CO; Dandoy CE; Marks DI; Lazarus HM; Abdel-Azim H; Bitan M; Diaz MA; Olsson RF; Gergis U; Seber A; Wirk B; LeMaistre CF; Ustun C; Duncan C; Rizzieri D; Szwajcer D; Fagioli F; Frangoul H; Knight JM; Kamble RT; Mehta P; Schears R; Satwani P; Pulsipher MA; Aplenc R; Saber W
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1747-1756. PubMed ID: 32464284
[TBL] [Abstract][Full Text] [Related]
10. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
Spinelli O; Giussani U; Borleri G; Lazzari M; Michelato A; Dotti G; Barbui T; Rambaldi A
Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
[TBL] [Abstract][Full Text] [Related]
11. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
12. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
Elliott MA; Tefferi A; Hogan WJ; Letendre L; Gastineau DA; Ansell SM; Dispenzieri A; Gertz MA; Hayman SR; Inwards DJ; Lacy MQ; Micallef IN; Porrata LF; Litzow MR
Bone Marrow Transplant; 2006 Jun; 37(11):1003-8. PubMed ID: 16604096
[TBL] [Abstract][Full Text] [Related]
13. Emergence of clone with PHF6 nonsense mutation in chronic myelomonocytic leukemia at relapse after allogeneic HCT.
Akahoshi Y; Nakasone H; Kusuda M; Kameda K; Nakamura Y; Kawamura M; Takeshita J; Kawamura S; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Tanihara A; Tamaki M; Kimura SI; Kako S; Kanda Y
Int J Hematol; 2022 May; 115(5):748-752. PubMed ID: 34988909
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
15. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
Itonaga H; Iwanaga M; Aoki K; Aoki J; Ishiyama K; Ishikawa T; Sakura T; Fukuda T; Najima Y; Yujiri T; Mori T; Kurokawa M; Nawa Y; Uchida N; Morishita Y; Hashimoto H; Eto T; Hirokawa M; Morishima Y; Nagamura-Inoue T; Atsuta Y; Miyazaki Y
Leuk Res; 2016 Feb; 41():48-55. PubMed ID: 26754557
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Analysis on Treatment of Chronic Myelomonocytic Leukemia with Allogeneic Hematopoietic Stem Cell Transplantation].
Wang T; Li WY; Qi XF; Zhang R; Jing ZM; Qiu HY; Han Y; Ma X; Fu CC; Tang XW; Chen SN; Sun AN; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1667-72. PubMed ID: 26708891
[TBL] [Abstract][Full Text] [Related]
17. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
18. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
Marks DI; Clifton-Hadley L; Copland M; Hussain J; Menne TF; McMillan A; Moorman AV; Morley N; Okasha D; Patel B; Patrick P; Potter MN; Rowntree CJ; Kirkwood AA; Fielding AK
Lancet Haematol; 2022 Apr; 9(4):e276-e288. PubMed ID: 35358442
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.
Liu HD; Ahn KW; Hu ZH; Hamadani M; Nishihori T; Wirk B; Beitinjaneh A; Rizzieri D; Grunwald MR; Sabloff M; Olsson RF; Bajel A; Bredeson C; Daly A; Inamoto Y; Majhail N; Saad A; Gupta V; Gerds A; Malone A; Tallman M; Reshef R; Marks DI; Copelan E; Gergis U; Savoie ML; Ustun C; Litzow MR; Cahn JY; Kindwall-Keller T; Akpek G; Savani BN; Aljurf M; Rowe JM; Wiernik PH; Hsu JW; Cortes J; Kalaycio M; Maziarz R; Sobecks R; Popat U; Alyea E; Saber W
Biol Blood Marrow Transplant; 2017 May; 23(5):767-775. PubMed ID: 28115276
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
